Association of CYP2C19 variants with the response to clopidogrel in Chinese ACS patients

Association of CYP2C19 variants with the response to clopidogrel in Chinese ACS patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OCH-11001767

Enrollment

Unknown

Registered

2011-12-05

Start date

2011-02-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary atherosclerotic heart disease

Interventions

Sponsors

Zhongshan Hospital, Fudan University

Lead Sponsor

Eligibility

Sex/Gender

All

Age

34 Years to 84 Years

Inclusion criteria

Inclusion criteria: Chinese patients with acute coronary syndrome, treated with clopidogrel and asipilin

Exclusion criteria

Exclusion criteria: Allergies or contraindications to either asipilin or clopidogrel; increased risk of bleeding; hematologic disorder; pregnancy; malignancy

Design outcomes

Primary

Measure	Time frame
genotype;activity of platele;	—

Countries

China

Contacts

Public ContactHongyi Wu

wu.hongyi@zs-hospital.sh.cn+86 13817165522

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026